Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Halozyme (HALO)

Halozyme adds James Lang to board of directors effective December 4, 2025

Neutral Impact 2 of 5 leadership Written later

Halozyme Therapeutics elected James Lang to its Board of Directors on December 4, 2025, with a term ending at the 2027 annual meeting. He was not initially assigned to any board committee, and the filing states there are no related person transactions or arrangements tied to his election.

Key points

  • James Lang elected to the Board of Directors on December 4, 2025
  • Term ends at the Company's annual meeting of stockholders in 2027
  • Not initially assigned to any Board committee
  • Compensated under the standard non-employee director program, described in the 2025 proxy statement

The filing

CompanyHalozyme (HALO)
Form8-K, current report
Filed with the SECDec 8, 2025, 5:20 PM ET
Accession number0001159036-25-000068

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 08, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.